Question 1

How does EquitAI evaluate 22nd Century Group, Inc.'s (XXII) valuation and Stock DNA?

Accepted Answer

22nd Century Group, Inc. (XXII) trades at $0.07 with an EquitAI Valuation DNA score of 7/10 and Quality score of 1/10. These scores evaluate balance sheet leverage, free cash flow generation, and fundamental multiples against historical benchmarks.

Question 2

What sector and industry does 22nd Century Group, Inc. (XXII) operate in?

Accepted Answer

22nd Century Group, Inc. (XXII) is classified under the Consumer Defensive sector within the Tobacco industry. EquitAI benchmarks its fundamental valuation and financial DNA metrics against both direct Tobacco peers and broader Consumer Defensive market benchmarks.

Question 3

What is Wall Street's price target and consensus rating for 22nd Century Group, Inc. (XXII)?

Accepted Answer

Wall Street analysts have a consensus 12-month price target of $1237.5 for 22nd Century Group, Inc. (XXII), representing an implied 1777917.2% upside from its current trading level of $0.07 with an average rating of Buy based on 2 analyst ratings. Individual analyst price targets range from a low of $1125.0 to a high of $1350.0, with a median forecast of $1237.5. EquitAI benchmarks analyst consensus projections against intrinsic Financial DNA valuation pillars.

Question 4

Does XXII pay dividends or capital distributions?

Accepted Answer

22nd Century Group, Inc. does not currently pay a regular dividend yield, prioritizing capital reinvestment into operations, product development, and balance sheet strength.

Question 5

Who are 22nd Century Group, Inc.'s (XXII) primary market competitors and peers?

Accepted Answer

Key market peers and semantic competitors include PM, BTI, MO, TPB. EquitAI maps peer relationships through semantic business models, institutional capital flow correlation, and market capitalization weighting.

Question 6

How should investors interpret EquitAI's XXII analysis?

Accepted Answer

EquitAI provides quantitative financial research, algorithmic DNA scores, and SEC contextual analytics for informational and research purposes. It does not constitute personalized financial advice or broker-dealer investment recommendations.

XXII - 22nd Century Group, Inc. Stock Analysis & Valuation

22nd Century Group, Inc.

FIT ANALYSIS

Recent SEC Filings & Insights